Development of the first myasthenia gravis patient registry in Latvia: a single-centre experience Authors: Arta Grosmane-Bataraga, Vladimirs Krutovs, Marija Roddate, Violeta Žukova, Gundega Ķauķe, Ieva Glāzere, Linda Gailīte, Nataļja Kurjāne, Viktorija Ķēniņa Published: 2026 ABSTRACT AbstractThis study describes the development of Latvia’s first myasthenia gravis (MG) patient registry in a single-centre setting. Adults with confirmed MG were recruited between January 2022 and May 2025 at Pauls Stradiņš Clinical University Hospital. Demographic and clinical data were collected, and patients were assessed using the MGFA Clinical Classification, MG Composite (MGC), MG-ADL, MGQOL15, and Fatigue Severity Scale (FSS). Data were stored in a secure digital registry. A total of 112 patients were enrolled (62/107 (55%) female, from the available data; mean age 57.2 years), with 523 visits recorded. Median disease duration was 4.5 years. Antibody profiles were 76% AChR, 4% anti-MuSK, and 6% seronegative, with 14% missing data. At baseline, 25% of patients were in remission; after a median follow-up of 1.3 years (IQR 0.8–1.9 years), remission increased to 34%, while MGFA classes III–IV declined from 19 to 2%. Median MGC, MG-ADL, and MGQOL15 scores improved significantly (p < 0.001). FSS improved modestly (45.5 → 42.0, p = 0.049), 50% reported relevant fatigue. Median prednisone dose decreased from 15.0 to 7.5 mg (p < 0.001). The registry demonstrates the feasibility of structured longitudinal data collection in MG, with clinical improvement observed during follow-up, although fatigue remains a persistent burden.Keywords: Myasthenia gravis, Rare disease, Patient registry, Neuroimmunology, Autoimmune diseasesSubject terms: Diseases, Medical research Introduction Myasthenia gravis (MG) is a rare, chronic autoimmune neuromuscular disease (ORPHA:589), characterised by its hallmark features of muscle weakness and fatigability1. The presence of antibodies in serum, the location of symptoms, and the age of onset are used to classify the disease. Known for its fluctuating symptoms and characteristic fatigue, MG imposes a considerable socioeconomic burden, both on individuals and globally. The disease has a profound impact on patients’ quality of life and their ability to work and carry out everyday tasks, and it also creates financial strain on national healthcare systems as well as on patients at a personal level2,3. Although several randomised controlled trials have recently evaluated novel targeted therapies in MG, long-term real-world data on effectiveness, safety, and patient-reported outcomes remain limited4,5. In the literature, patient registries—particularly for rare diseases—have proven to be essential tools for improving patient-centred care and advancing research. These registries facilitate systematic longitudinal data collection, enable real-world evaluation of treatment effectiveness and safety, support identification of prognostic factors, and improve patient recruitment into clinical trials. In rare diseases such as MG, they are particularly valuable for aggregating sufficiently large cohorts for meaningful analysis6,7. Several MG or neuromuscular disease registries already exist, both at a nationwide and a single-centre level8–12. In addition, global databases have been established, such as the myasthenia gravis patient registry (MGR), a voluntary patient-submitted database13, and MGBase, which seeks to develop a globally inclusive longitudinal patient registry14. Complementing these efforts, initiatives have also been made to harmonise data collection among European national registries, with the aim of establishing an enhanced European MG registry and fostering collaboration15. Nevertheless, there remains scope for improvement and cooperation to ensure the collection of adequate, clinically verified data—particularly relevant in patient-reported registries—and to achieve harmonised standardised clinical, therapeutic, and patient-reported outcomes of global significance16. In this paper, we describe the development of a regularly updated, longitudinally structured single-centre MG patient registry in Latvia and characterise the patient cohort using demographic and clinical data, as well as patient outcome measures, while also evaluating changes observed during follow-up. Methods Data collection Patient data were collected between January 2022 and May 2025. Patients were recruited during outpatient visits at the Pauls Stradiņš Clinical University Hospital’s Centre of Rare Neurological Diseases, one of the largest tertiary care hospitals in Latvia and a national referral centre for several rare diseases, including neuromuscular disorders. Currently, the majority of Latvian patients with MG (approximately 200 individuals) are continuously monitored at the Centre of Rare Neurological Diseases. The inclusion criteria were age 18 years or older and a confirmed diagnosis of MG, established on the basis of a combination of clinical, neurophysiological, and laboratory findings. Clinical criteria included the presence of characteristic fluctuating muscle weakness with fatigability and improvement after rest or treatment with acetylcholinesterase inhibitors. Neurophysiological findings included the characteristic decrement during repetitive nerve stimulation; laboratory findings included positive AChR or MuSK antibodies detected by ELISA. No specific exclusion criteria were applied; all the patients were invited to enrol and to participate in the registry. All adult patients (≥ 18 years) with a confirmed diagnosis of myasthenia gravis who attended the outpatient clinic were invited to participate in the registry. This aligns with the intention to capture a real-world cohort of patients treated at the centre. Upon providing consent, each patient was assigned a unique identification number by the study team to ensure pseudonymization of personal data. This identifier was used for all subsequent data collection and analysis, and to label all study documentation and biological samples. A certified neurologist assessed demographic and clinical data during the outpatient visit. Patients were evaluated according to the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification at baseline and at follow-up17, the myasthenia gravis composite (MGC) score, and the Myasthenia Gravis Activities of Daily Living scale (MG-ADL) score. MGC is a clinician-assessed composite score ranging from 0 to 50, evaluating symptom severity across several domains with a minimal clinically important difference (MCID) of 3 or more points18. The MG-ADL scale is an 8-item instrument ranging from 0 to 24, with higher scores indicating greater disease burden. It primarily reflects patient-reported symptoms affecting daily functioning, although it can also be completed with clinician during clinical visits. A change of ≥ 2 points is generally considered clinically meaningful19. Patients also completed two self-assessment scales: the 15-item myasthenia gravis quality of life questionnaire (MGQOL15), which is a patient-reported quality-of-life questionnaire ranging from 0–60, with higher scores reflecting worse quality of life20, and the Fatigue Severity Scale (FSS), which is a fatigue scale consisting of nine items scored 1–7 each (total score 9–63), with scores > 36 indicating clinically significant fatigue21. The MGFA classification was defined as the primary outcome, while MG-ADL, MGC, MGQOL15, and FSS were considered secondary outcomes. MG Composite was applied in its original, validated form; for FSS, MG-ADL, and MGQOL15, the validated Latvian versions were used. In addition, remission status was categorised as stable remission or pharmacological remission; a full MGFA Post-Intervention Status (MGFA-PIS) classification, including minimal manifestation status, was not systematically assessed. When classifying early-onset MG (EOMG) and late-onset MG (LOMG), EOMG was defined as disease onset before the age of 50 years, while LOMG was defined as onset at 50 years or older. Thymoma-associated MG was defined as MG occurring in patients with a histologically confirmed thymoma, reflecting a paraneoplastic autoimmune process22. At the first visit, a certified neurologist completed a specifically designated paper questionnaire, which included the patient’s anonymised identification number and demographic and clinical data, baseline MGFA Clinical Classification, other evaluation scale scores, and self-assessment measures. No identifying patient information was recorded on the questionnaire. Prior to each visit, blood samples were collected, processed, and labelled with the patient’s identification number and visit date for storage in a biobank at − 80 °C for future research. Follow-up visits were scheduled mainly every 1–4 months, with some exceptions based on patient needs. At this centre, most MG patients who are not enrolled in the study are followed every 3 months and can receive telephone consults if necessary. However, for the purposes of this study, patients were required to attend in-person visits at the centre so that clinical assessments and questionnaires could be completed in a standardised manner. During these visits, the neurologist completed a paper questionnaire designed for follow-up assessments, recording changes in clinical status, updates in treatment regimens, and outcome measures, including the MGFA-PIS classification, alongside other evaluation and self-assessment scales. During follow-up, treatment adjustments were performed according to routine clinical practice and were individualised based on patients’ clinical status. Because treatment modifications could occur at different time points across patients, they were not modelled as a fixed variable. For analysis of treatment change, information from the most recent documented follow-up visit was used. All completed paper questionnaires with anonymised data were collected by the nurse coordinator and stored securely. The data were subsequently retrospectively entered into the electronic registry platform by two resident neurologists at Pauls Stradiņš Clinical University Hospital. This approach was intended to improve data monitoring and quality control, as the researchers responsible for data entry could identify missing information and, when necessary, recheck or clarify the recorded data. However, during the study period, if neurologists wished to enter data directly into the electronic system during the consultation, they were given access to do so. Digital platform, registry, and data entry The patient registry was created on the Longenesis Engage platform, a digital patient engagement system that supports research projects, participant interaction, and compliance with data protection and privacy regulations23. Development of the registry took place from May to December 2021. Longenesis Engage is a secure platform designed for healthcare data collection and participant engagement. It complies with the highest data protection standards, including ISO 27001 and ISO 27701 certification, full alignment with the General Data Protection Regulation, and readiness for the European Health Data Space requirements. For robust electronic identification and authentication, the platform integrates with eParaksts and Smart-ID, allowing secure digital signatures where required. To safeguard privacy, all patients are pseudonymised through unique codes. This ensures that no directly identifying information is contained in the dataset, while maintaining the ability to link longitudinal data to the same individual for follow-up and prospective analyses. On the platform, the registry was registered under the Department of Molecular Biology at Rīga Stradiņš University. The author and several co-authors were designated as administrators and helped design the registry questionnaire, which enabled entry of anonymised patient data. Administrators could later modify or refine the questionnaire if necessary, with assistance from Longenesis Engage developers. During the study period, the questionnaire was not updated. All registry data were anonymised. Paper questionnaire data were entered into the platform by the first author (A.G.B.) and one co-author (V.K.), both of whom had administrative rights, or by the nurse coordinator. Certified neurologists could also register as administrators and enter data directly, should they choose to do so. Statistical analysis Continuous data were tested for normality using the Shapiro–Wilk test, which is commonly recommended for small to moderate sample sizes to determine whether parametric or non-parametric statistical tests should be applied. For normally distributed data, mean values were reported; for non-normally distributed data, median values were reported. Associations were evaluated using Spearman’s correlation, as all variables except age were not normally distributed and included ordinal data from clinical questionnaires. A chi-square test was used to assess whether changes in the proportion of patients with clinical fatigue (according to the FSS) were relevant as this test is suitable for comparing categorical frequency distributions. For non-parametric follow-up data, the Wilcoxon signed-rank test was applied as it is appropriate for comparing repeated measurements within the same participants when normal distribution cannot be assumed. Differences in secondary outcomes between sexes and between education levels were compared using the Mann–Whitney U test and the Kruskal–Wallis test, which are appropriate for ordinal and non-normally distributed data. Statistical significance was defined as p < 0.05, two-tailed. Statistical analyses were performed with IBM SPSS Statistics. Figures were created using Microsoft Excel. Ethical considerations All patients provided written informed consent prior to inclusion in the study. Unique patient identification numbers were used to protect data privacy. Data administrators had no access to confidential patient information, and no sensitive or identifying data were shared with third parties, including the Longenesis Engage platform. All data were anonymised prior to analysis. The Ethics Committee of Rīga Stradiņš University approved the study. Results Demographic and clinical data In total, 523 patient visits were recorded, with first-visit data available for 112 individuals. In five of these cases, basic demographic data such as sex, education level, or place of residence were missing, although some clinical and scale data were still available. Missing values were mainly related to incomplete completion of paper questionnaires during outpatient visits and were not associated with identifiable demographic or clinical characteristics. Among the 107 patients with complete demographic information, 55% (n = 59) were female. The mean age at first visit was 57.2 ± 15.3 years. Most patients (42%, n = 47) had higher education, 23% (n = 26) had secondary education, and 1% (n = 1) had only basic primary education; education data were unavailable for 34% (n = 38). Because the study was conducted in Riga, nearly half of the participants resided in Riga or the surrounding region (49%, n = 55). A further 26% lived in other parts of Latvia: Semigallia and Latgallia (each 8%, n = 9), as well as Courland and Vidzeme (each 10%, n = 12). Residence data were missing for 15 patients (13%). The median symptom duration was 4.5 years (interquartile range [IQR] = 1.5–10.1 years), and the median time from symptom onset to diagnosis was 0.3 years (IQR = 0.1–1.8 years). For additional analysis, we compared diagnostic delay between patients living in Riga and those in other regions. The median time from symptom onset to diagnosis was longer for patients outside Riga (median = 0.7 years, IQR = 0.1–2.0 years) than for those in Riga (median = 0.3 years, IQR = 0.1–2.2 years), but the difference was not statistically significant (Mann–Whitney U = 894.500, p = 0.414). Almost two-thirds of patients (63%, n = 67) reported fluctuating symptoms, based on patient self-report of daily or day-to-day variability in muscle weakness. Anti-acetylcholine receptor antibodies were present in 76% of patients (n = 85), anti-muscle-specific kinase antibodies were present in 4% (n = 4), and 6% (n = 7) were seronegative. Antibody data were unavailable for 14% (n = 16). Comorbidities were common: 15% (n = 17) had other autoimmune diseases, and 6% (n = 7) had oncological conditions. Regarding thymic abnormalities, four patients (4%) had thymic hyperplasia, 18 patients had thymoma-associated MG, while 16% had missing data on the thymus. In 15 cases out of the 22 (13%), patients had undergone thymectomy, while the rest of the patients were more likely to have been recently diagnosed and were still awaiting the procedure. Additional clinical data, including detailed descriptions of thymus pathology and pharmacological treatment, are summarised in Table 1. Table 1Clinical and demographic data.Total cohort, n = 112Sex, male/female45 (40%)/62 (55%)Missing data5 (5%)Age, years57.2 ± 15.3Disease duration, years4.5 [1.5–10.1]Time from symptom onset to diagnosis, years0.3 [0.1–1.8]Antibody status Anti-AChR85 (76%) Anti-MuSK4 (4%) Seronegative7 (6%) Missing data16 (14%) Early onset/late onset40 (36%) / 46 (41%) Thymoma-associated MG18 (16%) Missing data8 (7%)Thymic abnormalities Normal or involuted72 (64.0%) Hyperplasia4 (4%) Thymoma A5 (4%) Thymoma B10 (9%) Unknown type of thymoma3 (3%) Missing data18 (16%)Immunosuppressive treatment regimen at baseline CS23 (21%) Non-CS IS13 (12%) CS + non-CS IS50 (45%) No therapy/AChE-I only22 (20%) Missing data4 (4%)Additional treatment Rituximab3 (3%) Plasma exchange29 (27%) IvIg16 (15%)Data are presented as n (%), mean ± standard deviation, or median [interquartile range]. AChE-I, acetylcholine esterase inhibitors; AChR, acetylcholine receptor; CS, corticosteroids; IvIg, intravenous immunoglobulin; MuSK, muscle-specific kinase; non-CS IS, non-corticosteroid immunosuppressants. Clinical and demographic data. Data are presented as n (%), mean ± standard deviation, or median [interquartile range]. AChE-I, acetylcholine esterase inhibitors; AChR, acetylcholine receptor; CS, corticosteroids; IvIg, intravenous immunoglobulin; MuSK, muscle-specific kinase; non-CS IS, non-corticosteroid immunosuppressants. Primary and secondary outcomes during the first visit At baseline, the MGFA Clinical Classification showed a heterogeneous distribution: 14% of patients (n = 16) were in class I, 35% (n = 39) in class II, 16% (n = 18) in class III, and 3% (n = 3) in class IV. A quarter of the cohort (25%, n = 28) were already in total or pharmacological remission. MGFA classification data were unavailable for 7% (n = 8) of patients (Table 2). Table 2Primary and secondary outcomes on the first and last visits.First visit (n = 112)Last visit (n = 109)Wilcoxon Z, p valueMGFA classification I16 (14)14 (13) IIa18 (16)17 (15) IIb21 (19)14 (13) IIIa1 (1)1 (1) IIIb17 (15)1 (1) IVb3 (3)0 (0)Total or pharmacological remission28 (25)38 (35)Missing data8 (7)24 (22)N/AMG-ADL score (first visit n = 89; last visit n = 86)3.0 [0.0–5.3]1.0 [0.0–4.0]− 3.524, < 0.001MGC score (first visit n = 89; last visit n = 86)5.5 [0.0–10.0]3.0 [0.0–6.0]− 4.397, < 0.001MGQOL15 score (first visit n = 89; last visit n = 86)22.0 [14.0–37.0]20.0 [9.0–31.0]− 3.543, < 0.001FSS score (first visit n = 89; last visit n = 86)45.5 [26.5–55.0]42.0 [23.0–52.0]− 1.968, 0.049Data are presented as n (%) or median [interquartile range]. MGFA, Myasthenia Gravis Foundation of America; FSS, Fatigue Severity Scale; MGC, Myasthenia Gravis Composite; MG-ADL, Myasthenia Gravis Activities of Daily Living scale; MGQOL15, 15-item Myasthenia Gravis Quality of Life questionnaire. Primary and secondary outcomes on the first and last visits. Data are presented as n (%) or median [interquartile range]. MGFA, Myasthenia Gravis Foundation of America; FSS, Fatigue Severity Scale; MGC, Myasthenia Gravis Composite; MG-ADL, Myasthenia Gravis Activities of Daily Living scale; MGQOL15, 15-item Myasthenia Gravis Quality of Life questionnaire. Among the 89 patients with complete baseline scale data, the median FSS score was 45.5 (IQR = 26.5–55.0), with 59% (n = 63) experiencing clinically significant fatigue (FSS score > 36). The median MGC score was 5.5 (IQR = 0.0–10.0), the median MG-ADL score was 3.0 (IQR = 0.0–5.3), and the median MGQOL15 score was 22.0 (IQR = 14.0–37.0) (Table 2). No significant correlations were observed between delay to diagnosis and the MGQOL15 score (r = 0.140, p = 0.205), MG-ADL score (r = 0.099, p = 0.373), or FSS score (r = − 0.107, p = 0.338). A Mann–Whitney U test was performed to assess potential differences between sexes across the scales, but none reached significance (FSS: U = 803.500, p = 0.187; MGC: U = 816.000, p = 0.168; MG-ADL: U = 842.500, p = 0.306; MGQOL15: U = 970.000, p = 0.931). To examine possible differences in secondary outcomes by education level, the Kruskal–Wallis H test was applied, again with no significant results (FSS: H = 2.482, p = 0.289; MGC: H = 2.858, p = 0.240; MG-ADL: H = 1.868, p = 0.393; MGQOL15: H = 2.031, p = 0.362). Follow-up outcomes The median follow-up duration was 1.3 years (IQR = 0.8–1.9 years), with the median of three visits (IQR = 2–5) per patient during the study period. At the last visit, according to the MGFA classification, 13% of patients (n = 14) were in class I, 15% (n = 17) in class IIa, and 13% (n = 14) in class IIb. One patient each (1%) was classified as IIIa and IIIb, while no patients were classified in MGFA classes IV or V. Total or pharmacological remission was achieved by 34% (n = 38) of patients, while data were missing for 24% (n = 27) (Table 2). At the follow-up, 86 patients had complete follow-up scale data. The median FSS score decreased from 45.5 at baseline to 42.0 (IQR = 23.8–51.3) at follow-up (p = 0.049). However, the proportion of patients with clinically relevant fatigue declined only from 59 to 50%, which was not statistically significant (p = 0.110). The median MGC score decreased significantly from 5.5 to 3.0 (IQR = 0.0–6.0) (p < 0.001), while clinically meaningful improvement (≥ 3-point reduction in MGC) was observed in 37 patients (43%). MG-ADL score from 3.0 to 1.0 (IQR = 0.0–3.3) (p < 0.001), with 38% of patients (n = 33) experiencing clinically meaningful improvement (≥ 2-point reduction in MG-ADL). Similarly, MGQOL15 score improved from a median of 22.0 to 20.0 (IQR = 7.8–29.3) (p < 0.001). The analysis of changes in immunosuppressive treatment between the first and the last visit was restricted to patients with complete treatment data at both baseline and last follow-up (n = 90). At the last visit, 5% (n = 6) were using corticosteroids (CS) alone, and 20% (n = 22) were using a non-steroid immunosuppressant (NSIS) alone. Most patients (44%, n = 49) were on combination therapy with CS and NSIS, while 13% (n = 14) were not receiving any immunosuppressive therapy or were receiving AChE-I only (Fig. 1). Data were missing for 19% of patients (n = 22). Changes in immunosuppressive treatment regimens. This figure shows the number of patients using different immunosuppressive treatment regimens. CS, corticosteroids; NSIS, non-steroid immunosuppressants. During the study period, corticosteroid management varied among patients. Some patients initiated prednisone treatment during the study period and subsequently underwent dose tapering according to clinical response. Exploring CS treatment over time, 51% of patients (n = 57) were using CS at the time of their follow-up visits—predominantly prednisone (46%, n = 52) and, less frequently, methylprednisolone (5%, n = 5). The prednisone dose decreased significantly, from a median of 15.0 mg (IQR = 10–25 mg) at the first visit to 7.5 mg (IQR = 1.3–15.0 mg) at the last follow-up visit (Wilcoxon test, Z = − 4.173, p < 0.001). Changes in the methylprednisolone dose could not be analysed because only five patients were receiving this treatment during follow-up. There is no data on patients who underwent thymectomy during the study period. Discussion This paper presents the creation of the first MG patient registry in Latvia. While currently centred at P. Stradiņš Clinical University Hospital’s Centre of Rare Neurological Diseases, the broader aim is to develop a national registry for patients with MG and to establish collaborations with international registries. Such integration is essential not only for monitoring patients locally but also for expanding the pool of real-world data that can inform future research and the development of global treatment guidelines24. Data from this registry have already contributed to two published articles25,26. Although this is a single-centre study, approximately one quarter of patients (26%) came from other regions of Latvia. However, this distribution should be interpreted cautiously, as patients from outside Riga may be more likely to be referred to a tertiary care centre if they have more severe or complex disease. Future efforts should therefore prioritise improving both patient and physician education in Latvian regions, ensuring that individuals with suspected MG are at least referred to specialists in neuromuscular disorders. Our study shows that the median time from symptom onset to diagnosis was 0.3 years, with an IQR of 0.1–1.8 years. Previous studies have reported a mean diagnostic delay of 0.91 to 1.00 years27,28, but our analysis presents the median result because of the non-normal distribution of the data. While direct comparison is therefore difficult, our cohort may have experienced earlier diagnosis. When comparing diagnostic delay by region, patients living outside Riga showed a longer median delay than those in Riga, although the difference was not statistically significant. Assessing education as a possible factor that could affect secondary outcomes (fatigue, quality of life, and functional daily living), no differences were found. There is evidence that higher education is positively correlated with health literacy, which, in turn, is associated with a more advanced perception of illness, greater adherence to treatment, and affects the way patients report their symptoms29–31. More specifically, research shows that education, along with other factors, affects the quality of life of patients with myasthenia gravis32,33. In our cohort, neither of the secondary outcomes showed a difference by education level, but it should be emphasised that disease-specific quality of life is primarily driven by other factors, including disease activity, treatment response, comorbidities, and others. During follow-up, patients demonstrated significant improvements in functional outcomes and quality of life, alongside an increase in the proportion achieving total or pharmacological remission (according to MGFA-PIS) and a reduction in the median CS dose. Prior work has suggested that patients with MG tend to have better outcomes when monitored by neurologists specialising in neuromuscular disorders34. Moreover, the German guidelines recommend serial evaluations using validated tools in combination with patient-reported outcomes to guide treatment and improve individualised care35. Despite these improvements, the effect on fatigue was less clear. At the end of follow-up, 50% of patients continued to report significant fatigue in daily life. The reported prevalence of fatigue in MG generally ranges from 44 to 82%, but the underlying mechanisms of this hallmark symptom remain poorly understood36,37. Fatigue has been shown to correlate with other outcome measures, including MG-ADL, MGQOL15, and MGFA-PIS, and appears more strongly associated with female sex, depression, and daytime sleepiness36,38,39. While fatigue is likely multifactorial, hypotheses include chronic inflammation, and there is also evidence linking persistent human herpes virus infection with chronic fatigue syndrome40,41. Further, more detailed research is required to clarify the factors contributing to this often debilitating symptom. While analysing the data, it became evident that some demographic or clinical information was missing. In several cases, this was due to certified neurologists not completing the paper questionnaires correctly during outpatient visits, or failing to complete them at all. Some neurologists later obtained administrative rights on the Longenesis platform and entered the information directly. Local discussions revealed that the paper questionnaire was considered too inconvenient, which in turn reduced adherence to completing the electronic registry during patient visits. Rare disease registries can be an essential tool for supporting individualised care and advancing research; however, their effectiveness depends on a sufficient level of data quality control and adherence in both data collection and entry. Marques et al. concluded that several factors influence the quality of rare disease registries, including lack of time on the part of practitioners, as well as insufficient structure and standardisation. Individual attitudes and beliefs were also reported to have both positive and negative impacts on registry implementation, with some expressing doubts about whether a registry can truly safeguard patient privacy or translate into improved care and clinical outcomes42. Ali et al. outlined essential quality criteria for registries: a strong governance system including ethics approval, management structures, and policies; data quality, ensured by trained personnel and clear data definitions and standards; and a secure platform with restricted user access and defined procedures for handling potential data breaches43. All of these aspects should be carefully reviewed before planning further improvements to the registry. This study has several limitations. First, it represents a single-centre registry, which may limit the generalisability of the findings to the broader myasthenia gravis population. Although patients were referred from different regions of Latvia, the cohort may still reflect referral patterns typical of a tertiary care centre. Second, a controlled study design would provide stronger evidence regarding the impact of systematic follow-up. Third, some demographic and clinical variables were missing, mainly due to incomplete paper questionnaires during outpatient visits or retrospective data entry, which may have introduced information bias. Fourth, the median follow-up duration was relatively short, which limits the ability to assess long-term disease trajectories and treatment outcomes. In addition, the registry dataset did not capture the specific clinical indication or treatment schedule for therapies such as rituximab, plasma exchange, or intravenous immunoglobulin, making it impossible to distinguish whether these interventions were used as rescue therapy during exacerbations or as part of escalation or maintenance treatment. Finally, as the registry is still under development, some variables were not systematically collected during the early phases of data entry, highlighting the need for further standardisation and optimisation of data collection procedures. Conclusions In conclusion, this study provides the first descriptive overview of patients with myasthenia gravis included in the Latvian registry, including demographic characteristics, clinical features, and patient-reported outcomes. Continued expansion of the registry and longer follow-up will allow more detailed analyses of disease course, treatment patterns, and outcomes in this population. Abbreviations Acetylcholine esterase inhibitors Acetylcholine receptor Corticosteroids Fatigue Severity Scale General Data Protection Regulation International Business Machines Statistical Package for the Social Sciences Interquartile range Immunosuppressants Intravenous immunoglobulin Myasthenia gravis Myasthenia gravis Activities of Daily Living Myasthenia Gravis Composite Myasthenia Gravis Foundation of America Myasthenia Gravis Foundation of America Postintervention Status 15-Item Myasthenia Gravis Quality of Life questionnaire Muscle-specific kinase Not applicable Non-steroid (non-corticosteroid) immunosuppressants Standard deviation Author contributions MR, VŽ, GĶ, and VĶ enrolled patients and collected data during outpatient visits. AG, VK and MR reviewed the collected data, entered it into the registry, and performed data monitoring. AG exported the data from the registry, performed statistical analysis, and wrote the major part of the original manuscript. LG, NK and VĶ assisted with the study design, methodology and supervision. All authors read and approved the final manuscript. Funding Riga Stradiņš University has granted the following funding: RSU-ZG-2024/1-0036 “Discovering biomarkers in Myastenia Gravis: Insights into Fatigue, Immune Dysregulation, and Viral Infections” \5.2.1.1.i.0/2/24/I/CFLA/005 Doctoral study grant. Data availability The datasets used and analysed during the current study are available from the corresponding author on reasonable request. Declarations Competing interests The authors declare that they have no competing interests to disclose. Ethical approval The study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of Rīga Stradiņš University (approval number: 2-PĒK-4/70/2023, date: 10 January 2023). Written informed consent was obtained from all participants before their inclusion in the study, in accordance with the relevant ethical standards. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and analysed during the current study are available from the corresponding author on reasonable request.